Market research
NVV1.F Novavax, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 264.2
- Beta
- Not available
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6700024010
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 264.2
- Beta
- Not available
About
About Novavax, Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NVV1.F discussion.
5 years, 5 months ago
Novavax, Inc is currently in a long term uptrend where the price is trading 20.5% above its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.6.
Novavax, Inc's total revenue rose by 3072.2% to $280M since the same quarter in the previous year.
Its net income has dropped by 457.9% to $-178M since the same quarter in the previous year.
Finally, its free cash flow fell by 612.0% to $-171M since the same quarter in the previous year.
Based on the above factors, Novavax, Inc gets an overall score of 3/5.